[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-future-liver-remnant-flr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-future-liver-remnant-flr":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100472196",false,"NCT05428735","The DRAGON 2 Trial","An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE\u002FHVE) with PVE Alone in Patients with Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)","DRAGON 2","Inclusion Criteria:\n\n* Patients with primarily unresectable\u002F potentially resectable CRLM with a FLR \\\u003C30% (\\\u003C40% in chemotherapy damaged livers)\n* Patients with non-resected primary CRC may be included if there is an intention to resect the CRC after the liver treatment (liver first approach) or simultaneously during one of the liver procedures.\n* Patients with resectable or ablatable lung or brain metastases can be included (statement about the resectability of these extrahepatic metastases by a tumor board needs to be available)\n* 18 Years and older\n* Men and women\n* Able to understand the trial and provide informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating female.\n* Premenopausal females not able or willing to commit to oral contraception\n* Patients with prohibitive comorbidities, decision made by local team\n* Any patient with non-resectable or non-ablatable extrahepatic disease\n* Patients with hepatic malignancies other than CRLM\n* Progression of disease by RECIST criteria after cytoreduction chemotherapy\n* Complete response after conversion chemotherapy\n* Staging CT and (if indicated) CT\u002FMRI brain that demonstrates non-resectable extrahepatic disease\n* The anatomy of the liver or manifestation of tumors in relation to the liver veins prohibits the use of combined PVE\u002FHVE.","ALL","18 Years",{"count":19,"type":20},348,"ESTIMATED","INTERVENTIONAL",[23],"NA","In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE\u002FHVE (interventional group).",[26,27],"Colorectal Cancer Liver Metastases (CRLM)","Small Future Liver Remnant (FLR)","RECRUITING","2024-10-29",{"date":31,"type":32},"2024-11-01","ACTUAL",{"date":34,"type":32},"2022-04-01",{"date":36,"type":20},"2029-06-30",{"name":38,"class":39},"Maastricht University","OTHER",24,""]